Cargando…

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax

Bcl-2 is often upregulated in cancers to neutralize the BH3-only protein Bim at the mitochondria. BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2’s hydrophobic cleft and disrupting Bcl-2/Bim complexes. Some cancers with elevated Bcl-2 display poor responses towards BH3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vervloessem, Tamara, Akl, Haidar, Tousseyn, Thomas, De Smedt, Humbert, Parys, Jan B., Bultynck, Geert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762350/ https://www.ncbi.nlm.nih.gov/pubmed/29340082 http://dx.doi.org/10.18632/oncotarget.22898

Ejemplares similares

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015)

Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells
por: Kerkhofs, Martijn, et al.
Publicado: (2019)

Constitutive IP(3) signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP(3) receptor disruptor BIRD-2
por: Bittremieux, Mart, et al.
Publicado: (2018)

IP(3)R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP(3)R-derived peptide targeting the BH4 domain of Bcl-2
por: Akl, H, et al.
Publicado: (2013)

Extracellular and ER-stored Ca(2+) contribute to BIRD-2-induced cell death in diffuse large B-cell lymphoma cells
por: Bittremieux, Mart, et al.
Publicado: (2018)

Regulation of the Autophagic Bcl-2/Beclin 1 Interaction
por: Decuypere, Jean-Paul, et al.
Publicado: (2012)

Selective regulation of IP(3)-receptor-mediated Ca(2+) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
por: Monaco, G, et al.
Publicado: (2012)

IP(3) Receptors, Mitochondria, and Ca(2+) Signaling: Implications for Aging
por: Decuypere, Jean-Paul, et al.
Publicado: (2011)

STIM1 as a key regulator for Ca(2+ )homeostasis in skeletal-muscle development and function
por: Kiviluoto, Santeri, et al.
Publicado: (2011)

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models
por: Vervloessem, Tamara, et al.
Publicado: (2020)

The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP(3) receptor inhibition
por: Ivanova, Hristina, et al.
Publicado: (2016)

mTOR-Controlled Autophagy Requires Intracellular Ca(2+) Signaling
por: Decuypere, Jean-Paul, et al.
Publicado: (2013)

Alpha-Helical Destabilization of the Bcl-2-BH4-Domain Peptide Abolishes Its Ability to Inhibit the IP(3) Receptor
por: Monaco, Giovanni, et al.
Publicado: (2013)

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018)

Ryanodine receptors are targeted by anti-apoptotic Bcl-X(L) involving its BH4 domain and Lys87 from its BH3 domain
por: Vervliet, Tim, et al.
Publicado: (2015)

Polycystins and cellular Ca(2+) signaling
por: Mekahli, D., et al.
Publicado: (2012)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022)

Role of the inositol 1,4,5-trisphosphate receptor/Ca(2+)-release channel in autophagy
por: Parys, Jan B, et al.
Publicado: (2012)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

Intracellular Ca(2+) signaling: A novel player in the canonical mTOR-controlled autophagy pathway
por: Decuypere, Jean-Paul, et al.
Publicado: (2013)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
por: Yuan, Delin, et al.
Publicado: (2021)

BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis
por: Vervliet, Tim, et al.
Publicado: (2018)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

The Complex Effects of PKM2 and PKM2:IP(3)R Disruption on Intracellular Ca(2+) Handling and Cellular Functions
por: Lemos, Fernanda O., et al.
Publicado: (2023)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells
por: Alhoshani, Ali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7kgtdcj03knlc1tnhvjbimk2d